Revance Therapeutics, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

[GlobeNewswire] – NEWARK, Calif. — Revance Therapeutics, Inc. , a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the closing of its initial … moreView todays social media effects on RVNCView the latest stocks trending across Twitter. Click to view dashboardSee who Revance is hiring next, click here to view […]